Blog - INTERNET MÉDICA

Síndrome de Kinsbourne Online (Kinsbourne Syndrome)

Por Paulo Leite 17/06/2019

¨ A síndrome de Kinsbourne, também conhecida como síndrome opsoclonus-mioclônus ou opsoclônica-mioclônica-atáxica ou síndrome dos olhos e pés dançantes. É uma desordem neurológica rara que acomete principalmente crianças hígidas, entre 6 meses e 3 anos de idade, com prevalência de 1/5000000 nascimentos. O quadro sindrômico envolve opsoclonia, que é a movimentação rápida, involuntária e multidirecional (horizontal e vertical) dos olhos, mioclonia e ataxia cerebelar. É considerada uma síndrome paraneoplásica, devido a sua associação com neuroblastoma, ganglioneuroblastoma e, mais raramente, com hepatoblastoma. Em muitos pacientes, o diagnóstico inicial é inadequado, sendo estabelecido tardiamente no contexto diferencial de ataxia cerebelar aguda. O reconhecimento dessa doença é de suma importância, em vista da conhecida associação com neuroblastoma oculto, suas implicações prognósticas e devido a uma proporção considerável de pacientes que respondem clinicamente por meio de tratamento imunossupressor, como esteroides e imunoglobulina, entre outras terapias imunomodulatórias¨

■ Síndrome de Kinsbourne: relato de caso

D F S Lopes, D L Araújo, K C Fonseca et al

Rev Med Minas Gerais 2019, vol 29:e-2012

http://www.rmmg.org/artigo/detalhes/2492

■ Paraneoplastic opsoclonus-myoclonus syndrome secondary to melanoma metastasis from occult primary cancer

J D Mondragón, O Jimínez-Zarazúa, L N Vélez-Ramírez et al

Case Rep Neurol 2019, vol 11: 66-79

https://www.karger.com/Article/FullText/497034

■ Paraneoplastic opsoclonus myoclonus in a patient with pancreatic adenocarcinoma

Divine C. Nwafor, Ashley B. Petrone, Joseph M. Collins, Amelia K. Adcock

Case Rep Neurol Med. 2019; 2019: 3601026

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500640/

■ Opsoclonus myoclonus syndrome: a rare manifestation of dengue infection in a child

Soaham D. Desai, Fenil R. Gandhi, Anand Vaishnav

J Pediatr Neurosci. 2018 Oct-Dec; 13(4): 455–45

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413617/

■ Opsoclonus-myoclonus-ataxia syndrome associated with chikungunya and dengue virus co-infection

do Rosário MS, Giovanetti M, de Jesus PAP et al

Int J Infect Dis. 2018 Oct;75:11-14

https://www.ijidonline.com/article/S1201-9712(18)34480-1/fulltext

■ Síndrome de Kinsbourne: reporte de um caso

Paredes-Ebratt, Ângela Maria and Espinosa-García, Eugenia Teresa

Iatreia, Mar 2017, vol.30, no.1, p.81-8

http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-07932017000100081&lng=en&nrm=iso

■ Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study

Michael R. Pranzatelli, Elizabeth D. Tate, Nathan R. McGee

Front Neurol. 2017; 8: 468

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604058/

■ Postintervention acute opsoclonus myoclonus syndrome

Annelise Aquilina, Nicola Dingli, Josanne Aquilina

BMJ Case Rep. 2017; 2017: bcr2017219859

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534871/

■ Neonatal ospsoclonus-myoclonus syndrome: video-polygraphic EEG documentation of two cases with favorable outcome

G Capovilla, R Monni, F Boscaini et al

Clinical Cases jan 2017

https://www.ccrejournal.eu/materiale_cic/927_1_2/7867_neonatal/article.htm

■ Terapia inmunosupresora en síndrome de opsoclonus-mioclonusataxia associado a un neuroblastoma paravertebral

A Castañon-González, E Barragán-Pérez, G Hernández-Pliego, J C López-Valdés

Neurologia agosto 2017

https://www.elsevier.es/es-revista-neurologia-295-avance-resumen-terapia-inmunosupresora-sindrome-opsoclonus-mioclonus-ataxia-S0213485317302554

■ Anesthesia in a child with Kinsbourne syndrome: Does anesthesia technique matters?

N Nisa, P Talawar, B Vasudevan

Saudi J Anaesth. 2016 Oct-Dec; 10(4): 468–470

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044740/

■ Neuroblastoma presenting as opsoclonus-myoclonus: a series of six cases and review of literature

J P Meena, R Seth, B Chakrabarty et al

J Pediatr Neurosci 2016, vol 11 (4): 373-377

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314861/

■ Clinical and immunological features of opsoclonus-muoclonus syndrome in the era of neuronal cell surface antibodies

Thaís Armangué, Lidia Sabater, Estefanía Torres-Veja et al

JAMA Neurol. 2016 Apr; 73(4): 417–42

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823978/

■ Opsoclonus-myoclonus syndrome associated with a nasopharyngeal tumor in an adult: a case report

Bilal Gani Taib, Andrew J Kinshuck, Philip Milburn-McNulty, Lauren Fratalia, Leigh Forsyth, David Husband, Terry M Jones, Anu Jacob

J Med Case Rep. 2015; 9: 128

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456717/

■ ¨Dancing eye syndrome¨ secondary to opsoclonus-myoclonus syndrome in small-cell lung cancer

Laroumagne, Xavier Elharrar, B. Coiffard, J. Plojoux, H. Dutau, D. Breen, P. Astoul

Case Rep Med. 2014; 2014: 545490

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981168/

■ Síndrome de Kinsbourne: relato de caso.

Maranhão, Marcius Vinícius M., Holanda, Allana Cavalcanti Fulgino de and Tavares, Felipe Lira

Rev. Bras. Anestesiol., Jun 2013, vol.63, no.3, p.287-289

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-70942013000300010&lng=en&nrm=iso

■ Síndrome de Kinsbourne manifestando-se com quadro de encefalite pós-viral.

Andrade, Olberes Vitor B., Troster, Eduardo Juan and Cypel, Saul

Rev. paul. pediatr., Jun 2011, vol.29, no.2, p.300-304

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-05822011000200024&lng=en&nrm=iso

■ Síndrome de ospoclonos mioclonos causado por un neuroblastoma. Informe de un caso

G Dávila-Gutiérrez, J M Palacios-Acosta, A Guzmpan-Martiínez et al

Acta Pediatr Med 2010, vol 31 (1): 36-41

https://www.medigraphic.com/pdfs/actpedmex/apm-2010/apm101j.pdf

■ Causas no oncológicas del síndrome de Kinsbourne.

Barragán-Pérez, Eduardo et al.

Bol. Med. Hosp. Infant. Mex., Jun 2005, vol.62, no.3, p.189-194

http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1665-11462005000300005&lng=es&nrm=iso

■ Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Estratificação de Risco Cardiovascular

Novo endereço:

Consultório: Rua Padre Rolim 815/sala 815

Tel: 33245518 (Consulta Particular/Unimed)

– Centro Médico Unimed BH/Contagem/Pedro I

Belo Horizonte/MG/Brasil

CRMMG: 7026

Email: pfleite1873@gmail.com

Câncer de Mama Online (Breast Cancer)

Por Paulo Leite 16/06/2019

■ Management of cardiovascular disease in women with breast cancer

R Barish, F Lymce, K Unger, A Barac

Circulation 2019, vol 139: 1110-1120

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.039371

■ SEOM clinical guidelines in early stage breast cancer (2018)

Ayala de la Peña, R. Andrés, J. A. Garcia-Sáenz, et al

Clin Transl Oncol. 2019; vol 21(1): 18–30

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339657/

■ 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

F Cardoso, E Senkus, A Costa et al

Annals of Oncology 2018, vol 29 (8): 1634-1657

https://academic.oup.com/annonc/article/29/8/1634/5055519

■ Alterações na Modulação Autonômica Cardíaca em Mulheres com Câncer de Mama em Uso de Inibidores de Aromatase e sua Relação com Variáveis Bioquímicas

Gonzaga, Luana Almeida et al

Arq. Bras. Cardiol., May 2019, vol.112, no.5, p.555-563

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000500555&lng=pt&nrm=iso&tlng=pt (portuguese)

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000500555&lng=pt&nrm=iso&tlng=en (english)

■ Alteração Contrátil Segmentar Ventricular Esquerda é Preditor Independente de Cardiotoxicidade em Pacientes com Câncer de Mama em Tratamento Quimioterápico

Barros, Márcio Vinícius Lins de et al

Arq. Bras. Cardiol., Jan 2019, vol.112, no.1, p.50-56

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000100050&lng=pt&nrm=iso&tlng=pt (portuguese)

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000100050&lng=pt&nrm=iso&tlng=en (english)

■ Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board

S P Somashekhar, M –J Sepúlveda, S Publielli et al

Annals of Oncology 2018, vol 29 (2): 418-423

https://academic.oup.com/annonc/article/29/2/418/4781689

■ Genetic testing to guide risk-stratified screens for breast cancer

Ava Willoughby, Paul R. Andreassen, Amanda Ewart Toland

J Pers Med. 2019, vol 9(1): 15.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462925/

■ Overview of the genetic basis toward early detection of breast cancer

Sumadee De Silva, Kamani Hemamala Tennekoon, Eric Hamilton Karunanayake

Breast Cancer (Dove Med Press) 2019

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345186/

■ Repercussions of melatonin on the risk of breast cancer: a systematic review and meta-analysis

Veiga, Eduardo Carvalho de Arruda et al.

Rev. Assoc. Med. Bras., May 2019, vol.65, no.5, p.699-705

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500699&lng=pt&nrm=iso&tlng=en

■ Translation and cultural adaptation of the Breast Cancer Treatment Outcome Scale (BCTOS) into Brazilian Portuguese.

Vieira, René Aloisio da Costa et al.

Rev. Assoc. Med. Bras., July 2018, vol.64, no.7, p.627-634

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302018000700627&lng=pt&nrm=iso&tlng=en

■ . Influência do posicionamento do retalho linfonodal vascularizado na resposta ao tratamento cirúrgico do linfedema secundário ao câncer de mama..

Montag, Eduardo et al

Rev. Col. Bras. Cir., 2019, vol.46, no.2

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912019000200156&lng=en&nrm=is

■ Papel da ressonância magnética das mamas na avaliação do carcinoma ductal in situ.

Tajima, Carla Chizuru et al

Radiol Bras, Feb 2019, vol.52, no.1, p.43-47

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842019000100043&lng=en&nrm=iso&tlng=pt (portuguese)

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842019000100043&lng=en&nrm=iso&tlng=en (english)

■ The screening, diagnosis, treatment, and follow-up of breast cancer

A Wöckel, U Albert, W Janni et al

Dtsch Arztebl Int 2018, vol 115 (18): 316-323

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987060/

■ Risk-reducing mastectomy for the prevention of primary breast cancer

Liz Lostumbo, Judi Wallace, Henry Ko, Nora E Carbine

Cochrane Database Syst Rev. 2018 Apr; 2018(4): CD002748

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494635/

■ Epidemiological characteristics of an risk factors for breast cancer in the world

Zohre Momenimovahed, Hamid Salehiniya

Breast Cancer (Dove Med Press) 2019; 11: 151–164

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462164/

■ Axillary web syndrome following breast cancer surgery: symptoms, complications, and management strategies

LA Koehler, TC Haddad, DW Hunter, TM Tuttle

Breast Cancer (Dove Med Press) 2019; 11: 13–19

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304256/

■ Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

Nehad M Ayoub, Kamal M Al-Shami, Rami J Yaghan

Breast Cancer (Dove Med Press) 2019; 11: 53–69. Published online 2019 Jan

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340364/

■ Targeting stem cells in the realm of drug-resistant breast cancer

Pranay Dey, Maitreyi Rathod, Abhijit De

Breast Cancer (Dove Med Press) 2019; 11: 115–135

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410754/

■ Metastasis inhibition in breast cancer by targeting cancer cell extravasation

Márcia R Cominetti, Wanessa F Altei, Heloisa Sobreiro Selistre-de-Araujo

Breast Cancer (Dove Med Press) 2019; vol 11: 165–178

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497883/

■ Stain use and breast cancer survival – a Swedish Nationwide study

Signe Borgquist, Per Broberg, Jasaman Tojjar, Håkan Olsson

BMC Cancer. 2019; 19: 54

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330431/

■ Sarcomas of the breast: findings on mammography, ultrasound, and magnetic resonance imaging

Matsumoto, Renato Augusto Eidy Kiota et al.

Radiol Bras, Dec 2018, vol.51, no.6, p.401-406

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842018000600011&lng=en&nrm=iso&tlng=en

■ Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

T Bachelot, E Ciruelos, A Schneeweiss et al

Annals of Oncology 2018, vol 30 (5): 766-773

https://academic.oup.com/annonc/article/30/5/766/5364015

■ BEECH: a dose-finding run-in followed by a randomized phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancere, and in PIK3CA mutant sub-population

N C Turner, E Alarcón, A C Armstrong et al

Annals of Oncology 2018, vol 30 (5): 766-773

https://academic.oup.com/annonc/article/30/5/774/5376517

■ European cancer mortality predictions for the year 2019 with focus on breast cancer

M Malvezzi, G Carioli, P Bertuccio et al

Annals of Oncology 2018, vol 30 (5): 781-787

https://academic.oup.com/annonc/article/30/5/774/5376517

■ OlympiAD final overall survival and tolerability results: Olaparibib versus chemotherapy treatment of physician´s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

M E Robson, N Tung, P Conte et al

Annals of Oncology 2018, vol 30 (4): 558-566

https://academic.oup.com/annonc/article/30/4/558/5299440

■ Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Acionability of molecular Targets (ESCAT)

R Condorelli, F Mosele, B Verret et al

Annals of Oncology 2018, vol 30 (3): 365-373

https://academic.oup.com/annonc/article/30/3/365/5305018

■ Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShorHER randomized adjuvant for patients with early HER2+ breast cancer

M V Dieci, P Conte, G Bisagni et al

Annals of Oncology 2018, vol 30 (3): 418-423

https://academic.oup.com/annonc/article/30/3/418/5290085

■ Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer

E S Sokol, Y X Feng, D X Jin et al

Annals of Oncology 2019, vol 30 (1): 115-123

https://academic.oup.com/annonc/article/30/1/115/5181087

■ Nine weeks versus 1 year adjuvant transtuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

P Conte, A Frassoldati, G Bisagni et al

Annals of Oncology 2018, vol 30 (12): 2328-2333

https://academic.oup.com/annonc/article/29/12/2328/5096775

■ Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of hign-risk luminal breast cancer

P Cottu, V D´Hondt, S Dureau et al

Annals of Oncology 2018, vol 29 (12): 2334-2340

https://academic.oup.com/annonc/article/29/12/2334/5126820

■ Mutational mechanism of amplifications revealed by analysis of clustered rearrangements in breast cancers

D Glodizik,, C Purdie, I H Rye et al

Annals of Oncology 2018, vol 29 (11): 2223-2231

https://academic.oup.com/annonc/article/29/11/2223/5106670

■ Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors

M Diossy,L Reiniger, Z Sztupinszki et al

Annals of Oncology 2018, vol 29 (9): 1948-1954

https://academic.oup.com/annonc/article/29/9/1948/5039891

■ nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

D A Yardeley, R Coleman, P Conte et al

Annals of Oncology 2018, vol 29 (8): 1763-1770

https://academic.oup.com/annonc/article/29/8/1763/5033593

■ Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

F Poggio, M Bruzzone, M Ceppi et al

Annals of Oncology 2018, vol 29 (7): 1497-1508

https://academic.oup.com/annonc/article/29/7/1497/5026316

■ Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

G N Hortobagyi, S M Stemmer, H A Burris et al

Annals of Oncology 2018, vol 29 (7): 1541-1547

https://academic.oup.com/annonc/article/29/7/1541/4989216

■ Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with and anthracycline and resistant to taxane

M Martin, M Campone, I Bondarenko et al

Annals of Oncology 2018, vol 29 (5): 1195-1202

https://academic.oup.com/annonc/article/29/5/1195/4852792

■ RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

C Cruz, M Casgtroviejo-Bermejo, S Gutiérrez-Enríquezet al

Annals of Oncology 2018, vol 29 (5): 1203-1210

https://academic.oup.com/annonc/article/29/5/1203/4959904

■ Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer

R J hartmaier, S E Trabucco, N Priedigkeit et al

Annals of Oncology 2018, vol 29 (4): 872-880

https://academic.oup.com/annonc/article/29/4/872/4817340

■ Open-label randomized phase III trial of vinflunine versus and alkylating agent in patients with heavily pretreated metastatic breast cancer

J Cortes, J Perez-Garcia, C Levy et al

Annals of Oncology 2018, vol 29 (4): 881-887

https://academic.oup.com/annonc/article/29/4/881/4897992

■ Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

H S Rugo, V Diéras, K A Gelmon et al

Annals of Oncology 2018, vol 29 (4): 888-894

https://academic.oup.com/annonc/article/29/4/888/4817337

■ Unravelling triple-negative breast cancer molecular hereogeneity using an integrative multiomic analysis

Y Bareche, D Venet, M Ignatiadis et al

Annals of Oncology 2018, vol 29 (4): 895-902

https://academic.oup.com/annonc/article/29/4/895/4819112

■ Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers

N J Birkbak, Y Li, S Pathania et al

Annals of Oncology 2018, vol 29 (4): 903-909

https://academic.oup.com/annonc/article/29/4/903/4857262

■ Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

R Condorelli, L Spring, J O´Shaughnessy, L Lacroix et al

Annals of Oncology 2018, vol 29 (3): 640-645

https://academic.oup.com/annonc/article/29/3/640/4725051

■ Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

S M Swain, M S Ewer, G Viale et al

Annals of Oncology 2018, vol 29 (3): 646-653

https://academic.oup.com/annonc/article/29/3/646/4748818

■ Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)

P Sharma, W E Barlow, A K Godwin et al

Annals of Oncology 2018, vol 29 (3): 654-660

https://academic.oup.com/annonc/article/29/3/654/4774220

■ A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

A Gennary, Z Sun, U Hasler-Strub et al

Annals of Oncology 2018, vol 29 (3): 661-668

https://academic.oup.com/annonc/article/29/3/661/4710349

■ Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with an withut visceral metastases

N C Turner, R S Finn, M Martin et al

Annals of Oncology 2018, vol 29 (3): 669-680

https://academic.oup.com/annonc/article/29/3/669/4802189

■ Tracking evolution of aromatase inhibitor resistance with circulating tumor DNA analysis in metastatic breast cancer

C Fribbens, I G Murillas, M Beaney et al

Annals of Oncology 2018, vol 29 (1): 145-153

https://academic.oup.com/annonc/article/29/1/145/4344806

■ Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

H S Han, V Diéras, M Robson et al

Annals of Oncology 2018, vol 29 (1): 154-161

https://academic.oup.com/annonc/article/29/1/154/4282670

■ A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer

C Criscitiello, M A Bayar, G Curigliano et al

Annals of Oncology 2018, vol 29 (1): 162-169

https://academic.oup.com/annonc/article/29/1/162/4565501

■ A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

P Nuciforo, T Pascual, J Cortés et al

Annals of Oncology 2018, vol 29 (1): 170-177

https://academic.oup.com/annonc/article/29/1/170/4460101

■ Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial

V Möbus, C Jackisch, H J Lück et al

Annals of Oncology 2018, vol 29 (1): 178-185

https://academic.oup.com/annonc/article/29/1/178/4563565

■ Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients

N Nabieva, S Kellner, T Fehm et al

Annals of Oncology 2018, vol 29 (1): 186-192

https://academic.oup.com/annonc/article/29/1/186/4430373